Asia-Pacific Gene Therapy Market - 2025-2033
Asia-Pacific Gene Therapy Market Size - Industry Trends & Outlook
The Asia-Pacific gene therapy market size reached US$ 1.06 Billion in 2024 and is expected to reach US$ 14.59 Billion by 2033, growing at a CAGR of 34.1% during the forecast period 2025-2033.
Gene therapy is a cutting-edge treatment method that fixes or replaces faulty genes to help prevent or cure diseases.
The Asia-Pacific gene therapy market is witnessing rapid growth, fueled by rising investments in biotechnology, increasing prevalence of rare and genetic disorders, and supportive government initiatives across countries like China, Japan, and South Korea. Key trends include the growing adoption of CRISPR-based gene editing, expanding clinical trial pipelines, and strategic collaborations between biotech firms and academic institutions. However, high treatment costs and regulatory complexities remain major restraints. Opportunities lie in leveraging regional manufacturing capabilities and personalized medicine advancements to accelerate commercial rollout and improve patient access across the region.
Major economies like China, Japan, and India are playing pivotal roles in shaping the market’s trajectory. China leads in clinical trial activity and regulatory momentum, with recent approvals such as BBM-H901 for hemophilia B demonstrating its commitment to accelerating gene augmentation therapies.
Japan continues to set regulatory benchmarks with approvals like Roctavian for hemophilia A and significant investments in regenerative medicine under its expedited approval pathways.
Meanwhile, India is gaining traction with increased biotech funding, the growth of gene therapy research hubs, and the establishment of government-led initiatives to promote genomic medicine and local manufacturing.
The region’s focus on gene augmentation combined with strategic partnerships between local and global biotech firms, rising healthcare spending, and a large patient pool, positions Asia-Pacific as the fastest-growing and most dynamic gene therapy market in the world.
Asia-Pacific Gene Therapy Market Dynamics: Drivers & Restraints
Rising Funding and Investments by the Government and Companies for Gene Therapy Research are Expected to drive the Gene Therapy market
Rising funding and investments are expected to lead the market expansion. Governments are raising funds in setting up research centers, particularly gene therapy to treat a number of rare diseases as well as chronic diseases such as cancer, cardiovascular diseases, and others.
For instance, in April 2024, the President of India, Smt Droupadi Murmu, launched India’s first home-grown gene therapy for cancer at IIT Bombay. As this line of treatment, named “CAR-T cell therapy”, is accessible and affordable, it provides a new hope for the whole of humankind. She expressed confidence that it will be successful in giving new lives to countless patients.
Rising investments by companies to expand their businesses by launching their operations in different parts of the country are also expected to drive the market growth.
For instance, in February 2024, Miltenyi Biotec announced that it would launch its operations in India with its first office and invest in setting up the Miltenyi Innovation and Technology Center as the CGT Centre of Excellence (COE) in Hyderabad, India. This COE will be one of its first of its kind in India, where scientists, researchers, industry experts, and clinicians can get classroom-to-hands-on training on cell and gene therapy (CGT) approaches right from proof-of-concept to pre-clinical/clinical development and commercialization.
And also, on May 31, 2023 Laurus Labs announced that it has signed definitive agreements to acquire additional stake of 7.24% in Immunoadoptive Cell Therapy Private Limited (lmmunoACT), an advanced cell and gene therapy company for a cash consideration of Rs. 80 Crore.
High developmental and treatment costs
The high developmental and treatment costs of gene therapies are expected to hinder the gene therapy market growth. Despite potential health benefits, the high costs of cell and gene therapies are expected to reduce the adoption of these procedures. In developing countries in Asia-Pacific, it is difficult for many individuals to get treated using gene therapy.
Gene therapies often come with exorbitant price tags, typically ranging from USD 300,000 to USD 4 million per patient, depending on the specific treatment and condition being addressed. For instance, the gene therapy Zolgensma, which treats spinal muscular atrophy, is priced at approximately USD 2.1 million per patient. Such high costs pose significant challenges for healthcare providers, especially smaller employers and Medicaid programs, leading to increased insurance premiums and limiting access for many patients.
Asia-Pacific Gene Therapy Market Segment Analysis
The Asia-Pacific gene therapy market is segmented based on approach, vector type, technique, and application.
Technique:
The gene augmentation in the technique is expected to hold 42.3% of the Asia-Pacific gene therapy market
The gene augmentation segment is expected to hold a significant portion of the Asia-Pacific gene therapy market, driven by its growing use in treating inherited genetic disorders and the region’s rising investment in cutting-edge biotechnologies. Gene augmentation, which delivers functional copies of defective or missing genes, has seen accelerated development across Asia-Pacific.
For instance, in April 2025, Belief BioMed (BBM), in collaboration with Takeda China, recently received approval from the National Medical Products Administration (NMPA) for BBM-H901 (Dalnacogene Ponparvovec Injection). This gene augmentation therapy is designed for the treatment of adult patients with moderate to severe hemophilia B, highlighting the region's growing capabilities in advancing gene-based treatments for inherited disorders.
Asia-Pacific Gene Therapy Market Competitive Landscape
The top companies in the Asia-Pacific gene therapy market include Thermo Fisher Scientific Inc., Genepeutic Bio, Biosyngen, Wuxiapptec, Esco Aster, CytoMed Therapeutics, PHARMICELL Co., Ltd, AnGes MG, Inc, MediPost, Transcell Biologics, among others.
The Asia-Pacific gene therapy market report delivers a detailed analysis with 57 key tables, more than 46 visually impactful figures, and 168 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2024
The Asia-Pacific gene therapy market size reached US$ 1.06 Billion in 2024 and is expected to reach US$ 14.59 Billion by 2033, growing at a CAGR of 34.1% during the forecast period 2025-2033.
Gene therapy is a cutting-edge treatment method that fixes or replaces faulty genes to help prevent or cure diseases.
The Asia-Pacific gene therapy market is witnessing rapid growth, fueled by rising investments in biotechnology, increasing prevalence of rare and genetic disorders, and supportive government initiatives across countries like China, Japan, and South Korea. Key trends include the growing adoption of CRISPR-based gene editing, expanding clinical trial pipelines, and strategic collaborations between biotech firms and academic institutions. However, high treatment costs and regulatory complexities remain major restraints. Opportunities lie in leveraging regional manufacturing capabilities and personalized medicine advancements to accelerate commercial rollout and improve patient access across the region.
Major economies like China, Japan, and India are playing pivotal roles in shaping the market’s trajectory. China leads in clinical trial activity and regulatory momentum, with recent approvals such as BBM-H901 for hemophilia B demonstrating its commitment to accelerating gene augmentation therapies.
Japan continues to set regulatory benchmarks with approvals like Roctavian for hemophilia A and significant investments in regenerative medicine under its expedited approval pathways.
Meanwhile, India is gaining traction with increased biotech funding, the growth of gene therapy research hubs, and the establishment of government-led initiatives to promote genomic medicine and local manufacturing.
The region’s focus on gene augmentation combined with strategic partnerships between local and global biotech firms, rising healthcare spending, and a large patient pool, positions Asia-Pacific as the fastest-growing and most dynamic gene therapy market in the world.
Asia-Pacific Gene Therapy Market Dynamics: Drivers & Restraints
Rising Funding and Investments by the Government and Companies for Gene Therapy Research are Expected to drive the Gene Therapy market
Rising funding and investments are expected to lead the market expansion. Governments are raising funds in setting up research centers, particularly gene therapy to treat a number of rare diseases as well as chronic diseases such as cancer, cardiovascular diseases, and others.
For instance, in April 2024, the President of India, Smt Droupadi Murmu, launched India’s first home-grown gene therapy for cancer at IIT Bombay. As this line of treatment, named “CAR-T cell therapy”, is accessible and affordable, it provides a new hope for the whole of humankind. She expressed confidence that it will be successful in giving new lives to countless patients.
Rising investments by companies to expand their businesses by launching their operations in different parts of the country are also expected to drive the market growth.
For instance, in February 2024, Miltenyi Biotec announced that it would launch its operations in India with its first office and invest in setting up the Miltenyi Innovation and Technology Center as the CGT Centre of Excellence (COE) in Hyderabad, India. This COE will be one of its first of its kind in India, where scientists, researchers, industry experts, and clinicians can get classroom-to-hands-on training on cell and gene therapy (CGT) approaches right from proof-of-concept to pre-clinical/clinical development and commercialization.
And also, on May 31, 2023 Laurus Labs announced that it has signed definitive agreements to acquire additional stake of 7.24% in Immunoadoptive Cell Therapy Private Limited (lmmunoACT), an advanced cell and gene therapy company for a cash consideration of Rs. 80 Crore.
High developmental and treatment costs
The high developmental and treatment costs of gene therapies are expected to hinder the gene therapy market growth. Despite potential health benefits, the high costs of cell and gene therapies are expected to reduce the adoption of these procedures. In developing countries in Asia-Pacific, it is difficult for many individuals to get treated using gene therapy.
Gene therapies often come with exorbitant price tags, typically ranging from USD 300,000 to USD 4 million per patient, depending on the specific treatment and condition being addressed. For instance, the gene therapy Zolgensma, which treats spinal muscular atrophy, is priced at approximately USD 2.1 million per patient. Such high costs pose significant challenges for healthcare providers, especially smaller employers and Medicaid programs, leading to increased insurance premiums and limiting access for many patients.
Asia-Pacific Gene Therapy Market Segment Analysis
The Asia-Pacific gene therapy market is segmented based on approach, vector type, technique, and application.
Technique:
The gene augmentation in the technique is expected to hold 42.3% of the Asia-Pacific gene therapy market
The gene augmentation segment is expected to hold a significant portion of the Asia-Pacific gene therapy market, driven by its growing use in treating inherited genetic disorders and the region’s rising investment in cutting-edge biotechnologies. Gene augmentation, which delivers functional copies of defective or missing genes, has seen accelerated development across Asia-Pacific.
For instance, in April 2025, Belief BioMed (BBM), in collaboration with Takeda China, recently received approval from the National Medical Products Administration (NMPA) for BBM-H901 (Dalnacogene Ponparvovec Injection). This gene augmentation therapy is designed for the treatment of adult patients with moderate to severe hemophilia B, highlighting the region's growing capabilities in advancing gene-based treatments for inherited disorders.
Asia-Pacific Gene Therapy Market Competitive Landscape
The top companies in the Asia-Pacific gene therapy market include Thermo Fisher Scientific Inc., Genepeutic Bio, Biosyngen, Wuxiapptec, Esco Aster, CytoMed Therapeutics, PHARMICELL Co., Ltd, AnGes MG, Inc, MediPost, Transcell Biologics, among others.
The Asia-Pacific gene therapy market report delivers a detailed analysis with 57 key tables, more than 46 visually impactful figures, and 168 pages of expert insights, providing a complete view of the market landscape.
Target Audience 2024
- Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
- Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
- Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
- Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
- Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
- Supply Chain: Distribution and Supply Chain Managers.
- Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
- Academic & Research: Academic Institutions.
1. MARKET INTRODUCTION AND SCOPE
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Approach
2.4. Snippet by Vector Type
2.5. Snippet by Technique
2.6. Snippet by Application
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Funding and Investments by the Government and Companies for Gene Therapy Research
3.1.1.2. Increasing Incidence of Genetic Diseases
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. High Developmental and Treatment Costs
3.1.2.2. Safety Concerns Associated with Gene Therapy
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Technological Advancements
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Asia-Pacific Regulatory and Reimbursement Landscape
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
5. GENE THERAPY MARKET APPROACH OUTLOOK
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
5.1.2. Market Attractiveness Index, By Approach
5.2. Ex-Vivo*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. In-Vivo
6. GENE THERAPY MARKET VECTOR TYPE OUTLOOK
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vector Type
6.1.2. Market Attractiveness Index, By Vector Type
6.2. Viral Vectors*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Retrovirus
6.2.4. Lentivirus
6.2.5. Adeno-Associated Virus
6.2.6. Herpes Simplex Virus
6.2.7. Others
6.3. Non-Viral Vectors
7. GENE THERAPY MARKET TECHNIQUE OUTLOOK
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
7.1.2. Market Attractiveness Index, By Technique
7.2. Gene Replacement*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Gene Addition
7.4. Gene Editing
8. GENE THERAPY MARKET APPLICATION OUTLOOK
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Oncology*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Musculoskeletal Conditions
8.4. Blood Disorders
8.5. Rare Diseases
8.6. Others
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. Thermo Fisher Scientific Inc.*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.3. Financial Overview
10.1.3.1. Company Revenue
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.5. SWOT Analysis
10.2. Genepeutic Bio
10.3. Biosyngen
10.4. Wuxiapptec
10.5. Esco Aster
10.6. CytoMed Therapeutics
10.7. PHARMICELL Co., Ltd
10.8. AnGes MG, Inc
10.9. MediPost
10.10. Transcell Biologics
LIST NOT EXHAUSTIVE
11. ASSUMPTION AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope
2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS
2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Approach
2.4. Snippet by Vector Type
2.5. Snippet by Technique
2.6. Snippet by Application
3. DYNAMICS
3.1. Impacting Factors
3.1.1. Drivers
3.1.1.1. Rising Funding and Investments by the Government and Companies for Gene Therapy Research
3.1.1.2. Increasing Incidence of Genetic Diseases
3.1.1.3. XX
3.1.2. Restraints
3.1.2.1. High Developmental and Treatment Costs
3.1.2.2. Safety Concerns Associated with Gene Therapy
3.1.2.3. XX
3.1.3. Opportunity
3.1.3.1. Technological Advancements
3.1.3.2. XX
3.1.4. Impact Analysis
4. STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK
4.1. Market Leaders and Pioneers
4.1.1. Emerging Pioneers and Prominent Players
4.1.2. Established Leaders with Largest Marketing Brand
4.1.3. Market Leaders with Established Products
4.2. Latest Developments and Breakthroughs
4.3. Asia-Pacific Regulatory and Reimbursement Landscape
4.4. Porter’s Five Forces Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
5. GENE THERAPY MARKET APPROACH OUTLOOK
5.1. Introduction
5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Approach
5.1.2. Market Attractiveness Index, By Approach
5.2. Ex-Vivo*
5.2.1. Introduction
5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. In-Vivo
6. GENE THERAPY MARKET VECTOR TYPE OUTLOOK
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vector Type
6.1.2. Market Attractiveness Index, By Vector Type
6.2. Viral Vectors*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.2.3. Retrovirus
6.2.4. Lentivirus
6.2.5. Adeno-Associated Virus
6.2.6. Herpes Simplex Virus
6.2.7. Others
6.3. Non-Viral Vectors
7. GENE THERAPY MARKET TECHNIQUE OUTLOOK
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technique
7.1.2. Market Attractiveness Index, By Technique
7.2. Gene Replacement*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Gene Addition
7.4. Gene Editing
8. GENE THERAPY MARKET APPLICATION OUTLOOK
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Oncology*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Musculoskeletal Conditions
8.4. Blood Disorders
8.5. Rare Diseases
8.6. Others
9. COMPETITIVE LANDSCAPE AND MARKET POSITIONING
9.1. Competitive Overview and Key Market Players
9.2. Market Share Analysis and Positioning Matrix
9.3. Strategic Partnerships, Mergers & Acquisitions
9.4. Key Developments in Product Portfolios and Innovations
9.5. Company Benchmarking
10. COMPANY PROFILES
10.1. Thermo Fisher Scientific Inc.*
10.1.1. Company Overview
10.1.2. Product Portfolio
10.1.2.1. Product Description
10.1.2.2. Product Key Performance Indicators (KPIs)
10.1.3. Financial Overview
10.1.3.1. Company Revenue
10.1.3.2. Geographical Revenue Shares
10.1.3.3. Revenue Forecasts
10.1.4. Key Developments
10.1.4.1. Mergers & Acquisitions
10.1.4.2. Key Product Development Activities
10.1.4.3. Regulatory Approvals, etc.
10.1.5. SWOT Analysis
10.2. Genepeutic Bio
10.3. Biosyngen
10.4. Wuxiapptec
10.5. Esco Aster
10.6. CytoMed Therapeutics
10.7. PHARMICELL Co., Ltd
10.8. AnGes MG, Inc
10.9. MediPost
10.10. Transcell Biologics
LIST NOT EXHAUSTIVE
11. ASSUMPTION AND RESEARCH METHODOLOGY
11.1. Data Collection Methods
11.2. Data Triangulation
11.3. Forecasting Techniques
11.4. Data Verification and Validation
12. APPENDIX
12.1. About Us and Services
12.2. Contact Us
LIST OF TABLES
Table 1 Asia-Pacific Gene Therapy Market Value, By Approach, 2025, 2029 & 2033 (US$ Million)
Table 2 Asia-Pacific Gene Therapy Market Value, By Vector Type, 2025, 2029 & 2033 (US$ Million)
Table 3 Asia-Pacific Gene Therapy Market Value, By Technique, 2025, 2029 & 2033 (US$ Million)
Table 4 Asia-Pacific Gene Therapy Market Value, By Application, 2025, 2029 & 2033 (US$ Million)
Table 5 Asia-Pacific Gene Therapy Market Value, By Approach, 2025, 2029 & 2033 (US$ Million)
Table 6 Asia-Pacific Gene Therapy Market Value, By Approach, 2022-2033 (US$ Million)
Table 7 Asia-Pacific Gene Therapy Market Value, By Vector Type, 2025, 2029 & 2033 (US$ Million)
Table 8 Asia-Pacific Gene Therapy Market Value, By Vector Type, 2022-2033 (US$ Million)
Table 9 Asia-Pacific Gene Therapy Market Value, By Technique, 2025, 2029 & 2033 (US$ Million)
Table 10 Asia-Pacific Gene Therapy Market Value, By Technique, 2022-2033 (US$ Million)
Table 11 Asia-Pacific Gene Therapy Market Value, By Application, 2025, 2029 & 2033 (US$ Million)
Table 12 Asia-Pacific Gene Therapy Market Value, By Application, 2022-2033 (US$ Million)
Table 13 Thermo Fisher Scientific Inc.: Overview
Table 14 Thermo Fisher Scientific Inc.: Product Portfolio
Table 15 Thermo Fisher Scientific Inc.: Key Developments
Table 16 Genepeutic Bio: Overview
Table 17 Genepeutic Bio: Product Portfolio
Table 18 Genepeutic Bio: Key Developments
Table 19 Biosyngen: Overview
Table 20 Biosyngen: Product Portfolio
Table 21 Biosyngen: Key Developments
Table 22 Wuxiapptec: Overview
Table 23 Wuxiapptec: Product Portfolio
Table 24 Wuxiapptec: Key Developments
Table 25 Esco Aster: Overview
Table 26 Esco Aster: Product Portfolio
Table 27 Esco Aster: Key Developments
Table 28 CytoMed Therapeutics: Overview
Table 29 CytoMed Therapeutics: Product Portfolio
Table 30 CytoMed Therapeutics: Key Developments
Table 31 PHARMICELL Co., Ltd: Overview
Table 32 PHARMICELL Co., Ltd: Product Portfolio
Table 33 PHARMICELL Co., Ltd: Key Developments
Table 34 AnGes MG, Inc: Overview
Table 35 AnGes MG, Inc: Product Portfolio
Table 36 AnGes MG, Inc: Key Developments
Table 37 MediPost: Overview
Table 38 MediPost: Product Portfolio
Table 39 MediPost: Key Developments
Table 40 Transcell Biologics: Overview
Table 41 Transcell Biologics: Product Portfolio
Table 42 Transcell Biologics: Key Developments
Table 1 Asia-Pacific Gene Therapy Market Value, By Approach, 2025, 2029 & 2033 (US$ Million)
Table 2 Asia-Pacific Gene Therapy Market Value, By Vector Type, 2025, 2029 & 2033 (US$ Million)
Table 3 Asia-Pacific Gene Therapy Market Value, By Technique, 2025, 2029 & 2033 (US$ Million)
Table 4 Asia-Pacific Gene Therapy Market Value, By Application, 2025, 2029 & 2033 (US$ Million)
Table 5 Asia-Pacific Gene Therapy Market Value, By Approach, 2025, 2029 & 2033 (US$ Million)
Table 6 Asia-Pacific Gene Therapy Market Value, By Approach, 2022-2033 (US$ Million)
Table 7 Asia-Pacific Gene Therapy Market Value, By Vector Type, 2025, 2029 & 2033 (US$ Million)
Table 8 Asia-Pacific Gene Therapy Market Value, By Vector Type, 2022-2033 (US$ Million)
Table 9 Asia-Pacific Gene Therapy Market Value, By Technique, 2025, 2029 & 2033 (US$ Million)
Table 10 Asia-Pacific Gene Therapy Market Value, By Technique, 2022-2033 (US$ Million)
Table 11 Asia-Pacific Gene Therapy Market Value, By Application, 2025, 2029 & 2033 (US$ Million)
Table 12 Asia-Pacific Gene Therapy Market Value, By Application, 2022-2033 (US$ Million)
Table 13 Thermo Fisher Scientific Inc.: Overview
Table 14 Thermo Fisher Scientific Inc.: Product Portfolio
Table 15 Thermo Fisher Scientific Inc.: Key Developments
Table 16 Genepeutic Bio: Overview
Table 17 Genepeutic Bio: Product Portfolio
Table 18 Genepeutic Bio: Key Developments
Table 19 Biosyngen: Overview
Table 20 Biosyngen: Product Portfolio
Table 21 Biosyngen: Key Developments
Table 22 Wuxiapptec: Overview
Table 23 Wuxiapptec: Product Portfolio
Table 24 Wuxiapptec: Key Developments
Table 25 Esco Aster: Overview
Table 26 Esco Aster: Product Portfolio
Table 27 Esco Aster: Key Developments
Table 28 CytoMed Therapeutics: Overview
Table 29 CytoMed Therapeutics: Product Portfolio
Table 30 CytoMed Therapeutics: Key Developments
Table 31 PHARMICELL Co., Ltd: Overview
Table 32 PHARMICELL Co., Ltd: Product Portfolio
Table 33 PHARMICELL Co., Ltd: Key Developments
Table 34 AnGes MG, Inc: Overview
Table 35 AnGes MG, Inc: Product Portfolio
Table 36 AnGes MG, Inc: Key Developments
Table 37 MediPost: Overview
Table 38 MediPost: Product Portfolio
Table 39 MediPost: Key Developments
Table 40 Transcell Biologics: Overview
Table 41 Transcell Biologics: Product Portfolio
Table 42 Transcell Biologics: Key Developments
LIST OF FIGURES
Figure 1 Asia-Pacific Gene Therapy Market Value, 2022-2033 (US$ Million)
Figure 2 Asia-Pacific Gene Therapy Market Share, By Approach, 2024 & 2033 (%)
Figure 3 Asia-Pacific Gene Therapy Market Share, By Vector Type, 2024 & 2033 (%)
Figure 4 Asia-Pacific Gene Therapy Market Share, By Technique, 2024 & 2033 (%)
Figure 5 Asia-Pacific Gene Therapy Market Share, By Application, 2024 & 2033 (%)
Figure 6 Asia-Pacific Gene Therapy Market Y-o-Y Growth, By Approach, 2023-2033 (%)
Figure 7 Ex-Vivo Gene Therapy Market Value, 2022-2033 (US$ Million)
Figure 8 In-Vivo Gene Therapy Market Value, 2022-2033 (US$ Million)
Figure 9 Asia-Pacific Gene Therapy Market Y-o-Y Growth, By Vector Type, 2023-2033 (%)
Figure 10 Viral Vectors Vector Type in Asia-Pacific Gene Therapy Market Value, 2022-2033 (US$ Million)
Figure 11 Non-Viral Vectors Vector Type in Asia-Pacific Gene Therapy Market Value, 2022-2033 (US$ Million)
Figure 12 Asia-Pacific Gene Therapy Market Y-o-Y Growth, By Technique, 2023-2033 (%)
Figure 13 Gene Replacement Technique in Asia-Pacific Gene Therapy Market Value, 2022-2033 (US$ Million)
Figure 14 Gene Addition Technique in Asia-Pacific Gene Therapy Market Value, 2022-2033 (US$ Million)
Figure 15 Gene Editing Technique in Asia-Pacific Gene Therapy Market Value, 2022-2033 (US$ Million)
Figure 16 Asia-Pacific Gene Therapy Market Y-o-Y Growth, By Application, 2023-2033 (%)
Figure 17 Oncology Application in Asia-Pacific Gene Therapy Market Value, 2022-2033 (US$ Million)
Figure 18 Musculoskeletal Conditions Application in Asia-Pacific Gene Therapy Market Value, 2022-2033 (US$ Million)
Figure 19 Blood Disorders Application in Asia-Pacific Gene Therapy Market Value, 2022-2033 (US$ Million)
Figure 20 Rare Diseases Application in Asia-Pacific Gene Therapy Market Value, 2022-2033 (US$ Million)
Figure 21 Others Application in Asia-Pacific Gene Therapy Market Value, 2022-2033 (US$ Million)
Figure 22 Thermo Fisher Scientific Inc.: Financials
Figure 23 Genepeutic Bio: Financials
Figure 24 Biosyngen: Financials
Figure 25 Wuxiapptec: Financials
Figure 26 Esco Aster: Financials
Figure 27 CytoMed Therapeutics: Financials
Figure 28 PHARMICELL Co., Ltd: Financials
Figure 29 AnGes MG, Inc: Financials
Figure 30 MediPost: Financials
Figure 31 Transcell Biologics: Financials
Figure 1 Asia-Pacific Gene Therapy Market Value, 2022-2033 (US$ Million)
Figure 2 Asia-Pacific Gene Therapy Market Share, By Approach, 2024 & 2033 (%)
Figure 3 Asia-Pacific Gene Therapy Market Share, By Vector Type, 2024 & 2033 (%)
Figure 4 Asia-Pacific Gene Therapy Market Share, By Technique, 2024 & 2033 (%)
Figure 5 Asia-Pacific Gene Therapy Market Share, By Application, 2024 & 2033 (%)
Figure 6 Asia-Pacific Gene Therapy Market Y-o-Y Growth, By Approach, 2023-2033 (%)
Figure 7 Ex-Vivo Gene Therapy Market Value, 2022-2033 (US$ Million)
Figure 8 In-Vivo Gene Therapy Market Value, 2022-2033 (US$ Million)
Figure 9 Asia-Pacific Gene Therapy Market Y-o-Y Growth, By Vector Type, 2023-2033 (%)
Figure 10 Viral Vectors Vector Type in Asia-Pacific Gene Therapy Market Value, 2022-2033 (US$ Million)
Figure 11 Non-Viral Vectors Vector Type in Asia-Pacific Gene Therapy Market Value, 2022-2033 (US$ Million)
Figure 12 Asia-Pacific Gene Therapy Market Y-o-Y Growth, By Technique, 2023-2033 (%)
Figure 13 Gene Replacement Technique in Asia-Pacific Gene Therapy Market Value, 2022-2033 (US$ Million)
Figure 14 Gene Addition Technique in Asia-Pacific Gene Therapy Market Value, 2022-2033 (US$ Million)
Figure 15 Gene Editing Technique in Asia-Pacific Gene Therapy Market Value, 2022-2033 (US$ Million)
Figure 16 Asia-Pacific Gene Therapy Market Y-o-Y Growth, By Application, 2023-2033 (%)
Figure 17 Oncology Application in Asia-Pacific Gene Therapy Market Value, 2022-2033 (US$ Million)
Figure 18 Musculoskeletal Conditions Application in Asia-Pacific Gene Therapy Market Value, 2022-2033 (US$ Million)
Figure 19 Blood Disorders Application in Asia-Pacific Gene Therapy Market Value, 2022-2033 (US$ Million)
Figure 20 Rare Diseases Application in Asia-Pacific Gene Therapy Market Value, 2022-2033 (US$ Million)
Figure 21 Others Application in Asia-Pacific Gene Therapy Market Value, 2022-2033 (US$ Million)
Figure 22 Thermo Fisher Scientific Inc.: Financials
Figure 23 Genepeutic Bio: Financials
Figure 24 Biosyngen: Financials
Figure 25 Wuxiapptec: Financials
Figure 26 Esco Aster: Financials
Figure 27 CytoMed Therapeutics: Financials
Figure 28 PHARMICELL Co., Ltd: Financials
Figure 29 AnGes MG, Inc: Financials
Figure 30 MediPost: Financials
Figure 31 Transcell Biologics: Financials
